The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Overview of the clinical management of patients with MF
Ruben Mesa, MD, Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC, gives an overview of the management of patients with myelofibrosis (MF). He recommends that the majority of patients, even those who are low-risk, be on medical therapy and that high-risk patients be assessed for transplantation. Dr Mesa suggests that the four approved JAK inhibitors should be used in different settings: ruxolitinib and fedratinib are interchangeable in front-line or second-line settings, particularly in patients without significant cytopenia, whilst momelotinib is indicated for patients with anemia, and pacritinib for patients with a platelet count below 50,000. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
